EQS-News CureVac Announces Proposed Public Offering of Common Shares

TÜBINGEN, Germany/BOSTON, USA – February 6, 2023 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), announced today that it intends to offer $200 million of its common shares in an underwritten public offering. In addition, CureVac intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of common shares to be sold in the offering on the same terms and conditions. All of the shares in the offering are to be sold by CureVac N.V. The offering is subject to market and other conditions, and there can be no assurances as to whether or when the offering may be completed or as to the actual size or terms of the offering.

Goldman Sachs & Co. LLC, Jefferies LLC, and SVB Securities LLC are acting as bookrunners for the proposed offering. Van Lanschot Kempen (USA) Inc. is acting as lead manager for the proposed offering.

The offering is being made pursuant to an automatically effective shelf registration statement on Form F-3 filed with the U.S. Securities and Exchange Commission (“SEC”) on September 17, 2021. The offering may be made only by means of a base prospectus and a related prospectus supplement, copies of which will be available on the SEC’s website located at www.sec.gov or may be obtained from Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, telephone: 1-866-471-2526, facsimile: 212-902-9316 or by emailing prospectus-ny@ny.email.gs.com; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, New York 10022, by telephone at (877) 821-7388 or by email at Prospectus_Department@Jefferies.com; and SVB Securities LLC, Attention: Syndicate Department, 53 State Street, 40^th Floor, Boston, MA 02109, or by telephone at (800) 808-7525, ext. 6105, or by email at syndicate@svbsecurities.com.